WEKO3
アイテム
{"_buckets": {"deposit": "d270b4b0-ae78-4ac9-aff9-de2d77c69547"}, "_deposit": {"created_by": 2, "id": "10014", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "10014"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00010014", "sets": ["30"]}, "author_link": ["40410", "40408", "40413", "40393", "40411", "40392", "40414", "40396", "40405", "40395", "40389", "40402", "40390", "40400", "40403", "40398", "40407", "40399", "40401", "40387", "40388", "40397", "40391", "40406", "40404", "40412", "40409", "40394"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "1826", "bibliographicPageStart": "1820", "bibliographicVolumeNumber": "71", "bibliographic_titles": [{"bibliographic_title": "Annals of the Rheumatic Diseases"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objective: To compare reasons for discontinuation and drug retention rates per reason among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of discontinuation of biological agents due to adverse events (AE) in patients with rheumatoid arthritis (RA). Method: This prospective cohort study included Japanese RA patients who started infliximab (n=412, 636.0 patientyears (PY)), etanercept (n=442, 765.3 PY), or tocilizumab (n=168, 206.5 PY) as the first biological therapy after their enrolment in the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety (REAL) database. Drug retention rates were calculated using the Kaplan-Meier method. To compare risks of drug discontinuation due to AE for patients treated with these biological agents, the Cox proportional hazard model was applied. Results: The authors found significant differences among the three therapeutic groups in demography, clinical status, comorbidities and usage of concomitant drugs. Development of AE was the most frequent reason for discontinuation of biological agents in the etanercept and tocilizumab groups, and the second most frequent reason in the infliximab group. Discontinuation due to good control was observed most frequently in the infliximab group. Compared with etanercept, the use of infliximab (HR 1.69; 95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) was significantly associated with a higher risk of discontinuation of biological agents due to AE. Conclusions: Reasons for discontinuation are significantly different among biological agents. The use of infliximab and tocilizumab was significantly associated with treatment discontinuation due to AE compared with etanercept.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Annals of the Rheumatic Diseases, 71(11), pp.1820-1826; 2012", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "BMJ Publishing Group"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1136/annrheumdis-2011-200838", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2013 BMJ Publishing Group Ltd \u0026 European League Against Rheumatism. All rights reserved."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00034967", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Sakai, Ryoko"}], "nameIdentifiers": [{"nameIdentifier": "40387", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Michi"}], "nameIdentifiers": [{"nameIdentifier": "40388", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nanki, Toshihiro"}], "nameIdentifiers": [{"nameIdentifier": "40389", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Watanabe, Kaori"}], "nameIdentifiers": [{"nameIdentifier": "40390", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamazaki, Hayato"}], "nameIdentifiers": [{"nameIdentifier": "40391", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koike, Ryuji"}], "nameIdentifiers": [{"nameIdentifier": "40392", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nagasawa, Hayato"}], "nameIdentifiers": [{"nameIdentifier": "40393", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Amano, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "40394", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saito, Kazuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "40395", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yoshiya"}], "nameIdentifiers": [{"nameIdentifier": "40396", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "40397", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sumida, Takayuki"}], "nameIdentifiers": [{"nameIdentifier": "40398", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ihata, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "40399", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishigatsubo, Yoshiaki"}], "nameIdentifiers": [{"nameIdentifier": "40400", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsumi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "40401", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Koike, Takao"}], "nameIdentifiers": [{"nameIdentifier": "40402", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakajima, Atsuo"}], "nameIdentifiers": [{"nameIdentifier": "40403", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tamura, Naoto"}], "nameIdentifiers": [{"nameIdentifier": "40404", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujii, Takao"}], "nameIdentifiers": [{"nameIdentifier": "40405", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Dobashi, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "40406", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tohma, Shigeto"}], "nameIdentifiers": [{"nameIdentifier": "40407", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugihara, Takahiko"}], "nameIdentifiers": [{"nameIdentifier": "40408", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueki, Yukitaka"}], "nameIdentifiers": [{"nameIdentifier": "40409", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashiramoto, Akira"}], "nameIdentifiers": [{"nameIdentifier": "40410", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawakami, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "40411", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hagino, Noboru"}], "nameIdentifiers": [{"nameIdentifier": "40412", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyasaka, Nobuyuki"}], "nameIdentifiers": [{"nameIdentifier": "40413", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harigai, Masayoshi"}], "nameIdentifiers": [{"nameIdentifier": "40414", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ARD71_1820.pdf", "filesize": [{"value": "283.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 283700.0, "url": {"label": "ARD71_1820.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/10014/files/ARD71_1820.pdf"}, "version_id": "929f1db0-04c4-4704-b709-81c46451294f"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/30709", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-02-19"}, "publish_date": "2013-02-19", "publish_status": "0", "recid": "10014", "relation": {}, "relation_version_is_last": true, "title": ["Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules"], "weko_shared_id": -1}
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
http://hdl.handle.net/10069/30709
http://hdl.handle.net/10069/307093d05e4c7-6178-4242-86d3-63a99d4093ee
名前 / ファイル | ライセンス | アクション |
---|---|---|
ARD71_1820.pdf (283.7 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-02-19 | |||||
タイトル | ||||||
タイトル | Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Sakai, Ryoko
× Sakai, Ryoko× Tanaka, Michi× Nanki, Toshihiro× Watanabe, Kaori× Yamazaki, Hayato× Koike, Ryuji× Nagasawa, Hayato× Amano, Koichi× Saito, Kazuyoshi× Tanaka, Yoshiya× Ito, Satoshi× Sumida, Takayuki× Ihata, Atsushi× Ishigatsubo, Yoshiaki× Atsumi, Tatsuya× Koike, Takao× Nakajima, Atsuo× Tamura, Naoto× Fujii, Takao× Dobashi, Hiroaki× Tohma, Shigeto× Sugihara, Takahiko× Ueki, Yukitaka× Hashiramoto, Akira× Kawakami, Atsushi× Hagino, Noboru× Miyasaka, Nobuyuki× Harigai, Masayoshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objective: To compare reasons for discontinuation and drug retention rates per reason among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of discontinuation of biological agents due to adverse events (AE) in patients with rheumatoid arthritis (RA). Method: This prospective cohort study included Japanese RA patients who started infliximab (n=412, 636.0 patientyears (PY)), etanercept (n=442, 765.3 PY), or tocilizumab (n=168, 206.5 PY) as the first biological therapy after their enrolment in the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety (REAL) database. Drug retention rates were calculated using the Kaplan-Meier method. To compare risks of drug discontinuation due to AE for patients treated with these biological agents, the Cox proportional hazard model was applied. Results: The authors found significant differences among the three therapeutic groups in demography, clinical status, comorbidities and usage of concomitant drugs. Development of AE was the most frequent reason for discontinuation of biological agents in the etanercept and tocilizumab groups, and the second most frequent reason in the infliximab group. Discontinuation due to good control was observed most frequently in the infliximab group. Compared with etanercept, the use of infliximab (HR 1.69; 95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) was significantly associated with a higher risk of discontinuation of biological agents due to AE. Conclusions: Reasons for discontinuation are significantly different among biological agents. The use of infliximab and tocilizumab was significantly associated with treatment discontinuation due to AE compared with etanercept. | |||||
書誌情報 |
Annals of the Rheumatic Diseases 巻 71, 号 11, p. 1820-1826, 発行日 2012-11 |
|||||
出版者 | ||||||
出版者 | BMJ Publishing Group | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00034967 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1136/annrheumdis-2011-200838 | |||||
権利 | ||||||
権利情報 | © 2013 BMJ Publishing Group Ltd & European League Against Rheumatism. All rights reserved. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Annals of the Rheumatic Diseases, 71(11), pp.1820-1826; 2012 |